358 related articles for article (PubMed ID: 28092987)
1. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
2. Biology and treatment of myeloma related bone disease.
Terpos E; Christoulas D; Gavriatopoulou M
Metabolism; 2018 Mar; 80():80-90. PubMed ID: 29175022
[TBL] [Abstract][Full Text] [Related]
3. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
Yee AJ; Raje NS
Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
[TBL] [Abstract][Full Text] [Related]
4. Management of Myeloma Bone Lesions.
Du JS; Yen CH; Hsu CM; Hsiao HH
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
7. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
8. Molecular mechanisms, current management and next generation therapy in myeloma bone disease.
Heusschen R; Muller J; Duray E; Withofs N; Bolomsky A; Baron F; Beguin Y; Menu E; Ludwig H; Caers J
Leuk Lymphoma; 2018 Jan; 59(1):14-28. PubMed ID: 28573897
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches to myeloma bone disease: an evolving story.
Longo V; Brunetti O; D'Oronzo S; Dammacco F; Silvestris F
Cancer Treat Rev; 2012 Oct; 38(6):787-97. PubMed ID: 22494965
[TBL] [Abstract][Full Text] [Related]
10. Myeloma bone disease: pathogenesis, current treatments and future targets.
Walker RE; Lawson MA; Buckle CH; Snowden JA; Chantry AD
Br Med Bull; 2014 Sep; 111(1):117-38. PubMed ID: 25190762
[TBL] [Abstract][Full Text] [Related]
11. Myeloma bone disease: pathogenesis and treatment.
O'Donnell EK; Raje NS
Clin Adv Hematol Oncol; 2017 Apr; 15(4):285-295. PubMed ID: 28591104
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic targets in myeloma bone disease.
Webb SL; Edwards CM
Br J Pharmacol; 2014 Aug; 171(16):3765-76. PubMed ID: 24750110
[TBL] [Abstract][Full Text] [Related]
13. Management of bone disease in multiple myeloma.
Terpos E; Berenson J; Raje N; Roodman GD
Expert Rev Hematol; 2014 Feb; 7(1):113-25. PubMed ID: 24433088
[TBL] [Abstract][Full Text] [Related]
14. [Management of multiple myeloma-related bone disease].
Jurczyszyn A; Grosicki S; Czerniuk MR; Morga R; MaĆecki K; Skotnicki AB
Przegl Lek; 2013; 70(11):950-7. PubMed ID: 24697037
[TBL] [Abstract][Full Text] [Related]
15. Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts.
Faict S; Muller J; De Veirman K; De Bruyne E; Maes K; Vrancken L; Heusschen R; De Raeve H; Schots R; Vanderkerken K; Caers J; Menu E
Blood Cancer J; 2018 Nov; 8(11):105. PubMed ID: 30409995
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonate therapy in the treatment of multiple myeloma.
Lawson MA; Ashcroft J; Croucher PI
Curr Pharm Des; 2010; 16(27):3028-36. PubMed ID: 20722619
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibodies against RANKL and sclerostin for myeloma-related bone disease: can they change the standard of care?
Kleber M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Hematol; 2019 Aug; 12(8):651-663. PubMed ID: 31268745
[No Abstract] [Full Text] [Related]
18. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
Croucher PI; Shipman CM; Van Camp B; Vanderkerken K
Cancer; 2003 Feb; 97(3 Suppl):818-24. PubMed ID: 12548581
[TBL] [Abstract][Full Text] [Related]
19. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis.
Vessella RL; Corey E
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Criscitiello C; Viale G; Gelao L; Esposito A; De Laurentiis M; De Placido S; Santangelo M; Goldhirsch A; Curigliano G
Cancer Treat Rev; 2015 Feb; 41(2):61-8. PubMed ID: 25499997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]